These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 35503178)

  • 1. Cholesterol Metabolism in Chronic Kidney Disease: Physiology, Pathologic Mechanisms, and Treatment.
    Pan X
    Adv Exp Med Biol; 2022; 1372():119-143. PubMed ID: 35503178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease.
    Vaziri ND
    J Ren Nutr; 2010 Sep; 20(5 Suppl):S35-43. PubMed ID: 20797569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis.
    Li H; Yu XH; Ou X; Ouyang XP; Tang CK
    Prog Lipid Res; 2021 Jul; 83():101109. PubMed ID: 34097928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
    Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
    Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interpreting lipoproteins in nonalcoholic fatty liver disease.
    Nemes K; Åberg F
    Curr Opin Lipidol; 2017 Aug; 28(4):355-360. PubMed ID: 28441156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Lipid metabolism abnormalities in Chronic Kidney Disease].
    Bianchi S; Baronti A; Cominotto R; Bigazzi R
    G Ital Nefrol; 2016 Malattie Metaboliche e Rene; 33(S68):. PubMed ID: 27960010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesterol efflux capacity is impaired in subjects with an elevated Fatty Liver Index, a proxy of non-alcoholic fatty liver disease.
    van den Berg EH; Gruppen EG; Ebtehaj S; Bakker SJL; Tietge UJF; Dullaart RPF
    Atherosclerosis; 2018 Oct; 277():21-27. PubMed ID: 30170220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients.
    Bermudez-Lopez M; Forne C; Amigo N; Bozic M; Arroyo D; Bretones T; Alonso N; Cambray S; Del Pino MD; Mauricio D; Gorriz JL; Fernandez E; Valdivielso JM
    Expert Opin Ther Targets; 2019 Jul; 23(7):619-630. PubMed ID: 31100024
    [No Abstract]   [Full Text] [Related]  

  • 10. Metabolism, energetics, and lipid biology in the podocyte - cellular cholesterol-mediated glomerular injury.
    Merscher S; Pedigo CE; Mendez AJ
    Front Endocrinol (Lausanne); 2014; 5():169. PubMed ID: 25352833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD.
    Lamprea-Montealegre JA; Staplin N; Herrington WG; Haynes R; Emberson J; Baigent C; de Boer IH;
    Clin J Am Soc Nephrol; 2020 Jan; 15(1):47-60. PubMed ID: 31831577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD.
    Bajaj A; Xie D; Cedillo-Couvert E; Charleston J; Chen J; Deo R; Feldman HI; Go AS; He J; Horwitz E; Kallem R; Rahman M; Weir MR; Anderson AH; Rader DJ;
    Am J Kidney Dis; 2019 Jun; 73(6):827-836. PubMed ID: 30686529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile.
    Siddiqui MS; Fuchs M; Idowu MO; Luketic VA; Boyett S; Sargeant C; Stravitz RT; Puri P; Matherly S; Sterling RK; Contos M; Sanyal AJ
    Clin Gastroenterol Hepatol; 2015 May; 13(5):1000-8.e3. PubMed ID: 25311381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mediating role of atherogenic lipoproteins in the relationship between liver fat and coronary artery calcification.
    Björnson E; Samaras D; Adiels M; Kullberg J; Bäckhed F; Bergström G; Gummesson A
    Sci Rep; 2023 Aug; 13(1):13217. PubMed ID: 37580332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of cholesterol efflux capacity with plasmalogen levels of high-density lipoprotein: A cross-sectional study in chronic kidney disease patients.
    Maeba R; Kojima KI; Nagura M; Komori A; Nishimukai M; Okazaki T; Uchida S
    Atherosclerosis; 2018 Mar; 270():102-109. PubMed ID: 29407877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid disorders and their relevance to outcomes in chronic kidney disease.
    Vaziri ND; Norris K
    Blood Purif; 2011; 31(1-3):189-96. PubMed ID: 21228589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of glucolipid metabolism and complications in novel cluster-based diabetes subgroups: a retrospective study.
    Li X; Chen H
    Lipids Health Dis; 2023 Nov; 22(1):200. PubMed ID: 37990237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kidney function, cholesterol absorption and remnant lipoprotein accumulation in patients with diabetes mellitus.
    Sonoda M; Shoji T; Kimoto E; Okute Y; Shima H; Naganuma T; Motoyama K; Morioka T; Mori K; Fukumoto S; Shioi A; Koyama H; Emoto M; Inaba M
    J Atheroscler Thromb; 2014; 21(4):346-54. PubMed ID: 24335047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellular lipids are an independent cause of liver injury and chronic kidney disease in non alcoholic fatty liver disease-like context.
    Monteillet L; Gjorgjieva M; Silva M; Verzieux V; Imikirene L; Duchampt A; Guillou H; Mithieux G; Rajas F
    Mol Metab; 2018 Oct; 16():100-115. PubMed ID: 30100243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.